Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by MrMugsyon Mar 11, 2023 11:03am
183 Views
Post# 35332474

RE:RE:RE:Happy Long Term Investor

RE:RE:RE:Happy Long Term InvestorYa - I'm not worried about dilution and you bring up a good point about the warrants.

The past year and a half have seen some intereting developments and they were all brought on by the human liver issues.  Initially, the issue scared me but the reality of the gained learning hit me quickly.  I think the ROS was a timely development and it should make us stronger.  Not that I like the ROS development but we now know it was inevitable.  Not sure how much sooner we would have wanted to figure it out anyway - best that we filled the bank up with cash first.  A world of difference now that we have cash to work with.

Sure - we could have went to SVB for funding at this time ... hahaha !

The parallel path for acute/chronic and working on a better formulation is a perfect combination - what you'd expect to see from a company that isn't going to let these setbacks get in the way.

With any luck, end-of-year P2-acute helps drive this bus - sets us up with investor excitement and gets us thinking co-listing.  Issuing shares to drive additional co-listing demand is a perfect way to add a few more shares (if demand outstrips supply).  Going into 2024 could also allow us to bank a few more dollars from expiring warrants - if - they can pull off a very nice P2-Acute readout.

Also ... DILIsym should be a powerful tool for our needs.  First with Acute, then with IBD ... and ... finally with Chronic (based on the fact we're using it in acute now).

Time will tell where we are - but - I like how it's coming together.
<< Previous
Bullboard Posts
Next >>